Table 3 Physicochemical characteristics and metabolic stability of AmyP53 in vitro.

From: Preclinical assessment of a ganglioside-targeted therapy for Parkinson’s disease with the first-in-class adaptive peptide AmyP53

Matrix

AmyP53

t1/2

Propantheline

t1/2

AmyP53 bound to plasma protein %

Propranolol bound to plasma protein %

Rat plasma

787 min

227 min

93.4 ± 0.6

89.8 ±0.1

Rabbit plasma

601 min

17 min

81.7 ±0.8

74.8 ±1.1

Mini-pig plasma

364 min

179 min

81.4 ±0.8

85.2 ±0.9

Dog plasma

83 min

104 min

84.6 ±4.3

86.5 ±1.0